Idiopathic Inflammatory Myopathy (IIM) (or myositis) associated interstitial lung disease (MA-ILD) leads to significant morbidity and mortality, and there are no approved or consensus-driven treatments. Though immunosuppressive drugs are often helpful in MA-ILD, the establishment of additional effective and safe therapies remains a significant unmet need for MA-ILD patients with progressive fibrosis. Nintedanib, a tyrosine kinase inhibitor approved as an anti-fibrotic agent, could meet this critical need. The aggregate of trial data for nintedanib support its efficacy in all forms of progressive fibrosing ILD—whether idiopathic or autoimmune. The role of nintedanib in MA-ILD remains unclear even though retrospective studies suggest it is safe and efficacious in combination with standard immunosuppression. Traditional clinical trial design in rare disease often suffers from a scarcity of patients at any given center leading to difficulties with recruitment and prolonged study timelines. Recent advances in decentralized clinical trial design have enabled greater patient access, more rapid enrollment, and reduced cost without sacrificing study integrity. We have constructed MINT with these factors in mind.